Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ML-193 (CID 1261822) is a potent and selective GPR55 antagonist( IC50 : 221 nM). It shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2, and can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
2 mg | 在庫あり | ¥ 10,000 | |||
5 mg | 在庫あり | ¥ 16,000 | |||
10 mg | 在庫あり | ¥ 26,000 | |||
25 mg | 在庫あり | ¥ 43,500 | |||
50 mg | 在庫あり | ¥ 65,000 | |||
100 mg | 在庫あり | ¥ 97,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 22,000 |
説明 | ML-193 (CID 1261822) is a potent and selective GPR55 antagonist( IC50 : 221 nM). It shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2, and can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats. |
ターゲット&IC50 | GPR55:221 nM |
In vitro | ML193, a selective GPR55 antagonist.?ML184 significantly promoted neuronal differentiation in vitro while ML193 reduced differentiation rates as compared to vehicle treatment.Continuous administration of O-1602 into the hippocampus via a cannula connected to an osmotic pump resulted in increased Ki67+ cells within the dentate gyrus.?O-1602 increased immature neuron generation, as assessed by DCX+ and BrdU+ cells, as compared to vehicle-treated animals.?GPR55-/- animals displayed reduced rates of proliferation and neurogenesis within the hippocampus while O-1602 had no effect as compared to vehicle controls[2]. |
In vivo | Intra-striatal administration of ML193 increased time on the rotarod, decreased latency to remove the label and slip steps in 6-OHDA-lesioned rats mostly at the dose of 1 g/rat[1]. |
別名 | CID 1261822 |
分子量 | 527.59 |
分子式 | C28H25N5O4S |
CAS No. | 713121-80-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/ml (113.72 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ML-193 713121-80-3 GPCR/G Protein Cannabinoid Receptor Inhibitor deficits motor ML193 CID 1261822 sensorimotor ML 193 G protein-coupled receptor 55 disease Parkinson CID1261822 CID-1261822 inhibit GPR55 inhibitor